{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Zinc Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_2",
        "name": "Experimental Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_3",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_4",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7
      },
      {
        "id": "timing_5",
        "name": "End of Study Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_6",
        "name": "Dose Escalation Timing",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_7",
        "name": "Chelator Discontinuation Prior to Baseline",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_8",
        "name": "Pregnancy Test Frequency",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Safety Review for Dose Escalation",
        "instanceType": "Condition",
        "description": "Safety Review Committee (SRC) must review safety data before dose escalation from 15 mg/day to 30 mg/day.",
        "text": "Before titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_2",
        "name": "ALT Elevation for Dose Interruption",
        "instanceType": "Condition",
        "description": "Alanine aminotransferase (ALT) elevation criteria for temporary dose interruption.",
        "text": "ALT > 3 × ULN and ≤ 5 × ULN"
      },
      {
        "id": "cond_3",
        "name": "ALT Elevation for Discontinuation",
        "instanceType": "Condition",
        "description": "Alanine aminotransferase (ALT) elevation criteria for permanent study intervention discontinuation.",
        "text": "ALT > 5 × ULN"
      },
      {
        "id": "cond_4",
        "name": "Neutropenia for Dose Reduction",
        "instanceType": "Condition",
        "description": "Neutrophil count decrease criteria for dose reduction.",
        "text": "Neutrophils > 50% ↓ from baseline and below reference range"
      },
      {
        "id": "cond_5",
        "name": "Neurologic Worsening",
        "instanceType": "Condition",
        "description": "Clinical evidence of neurologic worsening that may trigger a dose modification evaluation.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_6",
        "name": "Adaptive Outpatient Period Extension",
        "instanceType": "Condition",
        "description": "Condition allowing for the extension of the outpatient period.",
        "text": "To ensure flexibility, the Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Escalation to 30mg",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "Participants will be administered ALXN1840 at 15 mg/day on Day 1 through Day 28 and then increase to 30 mg/day on Day 29 through Day 39."
      },
      {
        "id": "trans_2",
        "name": "Dose Interruption for ALT Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT is > 3 × ULN and ≤ 5 × ULN, temporary interruption of dosing is required."
      },
      {
        "id": "trans_3",
        "name": "Dose Reduction for Neutropenia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Neutrophils > 50% ↓ from baseline and below reference range, reduce dose to previous dose level or 15 mg QOD."
      },
      {
        "id": "trans_4",
        "name": "Intervention Discontinuation for Severe ALT Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If ALT is > 5 × ULN, discontinue study intervention."
      },
      {
        "id": "trans_5",
        "name": "Intervention Discontinuation for Pregnancy",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if Pregnancy or planned pregnancy occurs."
      },
      {
        "id": "trans_6",
        "name": "Intervention Discontinuation for Disallowed Medication",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if Use of disallowed medication occurs."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (SoA)."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal of Consent",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretionary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Study Termination by Sponsor",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of Alexion."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Escalation Safety Review",
        "timepointId": "Day 23",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for the Safety Review Committee to approve dose escalation based on safety data through Day 23.",
        "conditionIds": [
          "cond_1"
        ]
      },
      {
        "id": "dec_2",
        "name": "Dose Modification for Liver Function",
        "timepointId": "Unscheduled",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Unscheduled decision point to modify or discontinue dose based on clinically significant ALT elevations.",
        "conditionIds": [
          "cond_2",
          "cond_3"
        ]
      },
      {
        "id": "dec_3",
        "name": "Dose Modification for Neurologic Worsening",
        "timepointId": "Unscheduled",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Unscheduled decision point where the Investigator and Medical Monitor evaluate the need for dose modification based on neurologic worsening.",
        "conditionIds": [
          "cond_5"
        ]
      }
    ],
    "summary": {
      "timingCount": 8,
      "conditionCount": 6,
      "transitionRuleCount": 6,
      "exitCount": 5
    }
  }
}